Portrait of a woman with curly brown hair wearing a dark denim shirt, standing in front of an orange background.

Enabling the next era of informed cancer care

Exact Sciences delivers the promise and value of precision medicine with the Oncotype DX® test.

The Oncotype DX Breast Recurrence Score® test – bringing clarity to treatment decisions:

Uniquely designed

Uniquely designed to help identify patients who need chemotherapy1-3

Gold Standard

The gold standard to avoid over- and undertreatment4

Triple tested

Triple tested in a centralised laboratory with a short time to result5

What is the Oncotype DX test video.
How Oncotype DX works and how it can help guide a tailored chemotherapy treatment decision for your HR+, HER2-, early-stage breast cancer patients

Oncotype DX Test results trusted by many worldwide

1.5 million
patients tested5
90+
countries served5
Highest level of evidence
Recommended by all International Guidelines4,6-8,9-15
Picture of the Oncotype DX package
NEW DATA

Oncotype DX
Breast Recurrence Score®

The only multigene assay proven to predict a patient’s individual benefit from chemotherapy

Improving patient outcomes

Lady smiling outside
What is the test?
A 21-gene genomic test, including 16 cancer-related genes and 5 reference genes1,2
Scientist working in a laboratory
Why test?
To help determine whether an individual diagnosed with early-stage breast cancer may benefit from chemotherapy and to quantify their individual risk of recurrence2,4,6,7,16
Older lady sitting a beach in the sunshine
What information does the test provide?
The Oncotype DX® report provides three key pieces of information to help inform personalised treatment decisions.

References

  1. Paik et al NEJM. 2004,
  2. Paik et al. JCO. 2006,
  3. Sparano and Paik JCO. 2008,
  4. Sparano et al. NEJM. 2018,
  5. Exact Sciences, Data on file
  6. Kalinsky. N Engl J Med. 2021.
  7. Kalinsky et al. SABCS. 2021 GS2-07.
  8. Nitz et al. Breast Cancer Res Treat. 2017
  9. NCCN Guidelines. Version 4.2023. Available at: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 24, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  10. Andre et al. J Clin Oncol. 2022.
  11. Curigliano et al. Ann Oncol. 2023.
  12. Loibl et al. Annals of Oncology 2024 
  13. NICE Diagnostics guidance [DG58] 2024. Available at: https://www.nice.org.uk/guidance/dg58 Accessed: 09 May 2024.
  14. IQWiG Press Release, Addendum D18-01. 2018. Available at: https://www.iqwig.de/en/projects/d18-01.html Accessed: May 24, 2022
  15. IQWiG Report [D23-01], Biomarkers in primary breast cancer. Available at: https://www.iqwig.de/en/projects/d23-01.html Accessed: 18 November 2024.
  16. Albain et al. Lancet Oncol. 2010.
Get in touch
Have questions about Oncotype DX®?
Doctor sitting with patient having a discussion.